Skip to main content

Dana Farber Taps CLC Bio Platform for NGS Data Analysis


CLC Bio said this week that the Center for Cancer Computational Biology at the Dana-Farber Cancer Institute has selected CLC's enterprise platform to handle its next-generation sequence analysis needs.

Mick Correll, associate director of the CCCB, said the institute deployed CLC Bio's platform to support an "increasing number of molecular biologists and clinicians who don't have their own bioinformatics resources."

CLC Bio's platform provides "versatile deployment opportunities," he said. "By giving individual groups access to our central installation of the CLC Genomics Server, they can leverage a powerful enterprise platform while only needing to invest in their own desktop clients."

Currently, Dana-Farber os building the data-coordination and -analysis informatics infrastructure for the Lung Genomics Research Consortium, which aims to add genetic, genomic, and epigenetic data and analysis tools to an existing clinical biorepository at the National Heart Lung and Blood Institute (BI 02/11/2011).

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.